BioCentury
ARTICLE | Company News

QLT's Visudyne sNDA gets priority review

August 29, 2000 7:00 AM UTC

QLTI and partner Ciba Vision will receive priority FDA review for an sNDA for QLTI's Visudyne photodynamic therapy to treat patients with choroidal neovascularization (CNV) caused by macular diseases ...